OPR - Delayed Quote • USD BPMC Jun 2024 115.000 call (BPMC240621C00115000) Follow 2.5000 -0.4500 (-15.25%) As of April 26 at 11:11 AM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for BPMC240621C00115000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: BPMC Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Blueprint Medicines Corporation (NASDAQ:BPMC): When Will It Breakeven? Insiders Are Dumping These 10 Healthcare Stocks CRISPR Therapeutics (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound? Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report? 30 Biggest Biotechnology Companies in the World Blueprint Medicines Corp's Chief Commercial Officer Sells Company Shares Moderna (MRNA) Soars 8.7%: Is Further Upside Left in the Stock? Q4 2023 Rigel Pharmaceuticals Inc Earnings Call
